We previously reported that the Fourth Circuit, via a 2-1 decision in United States ex rel. Sheldon v. Allergan Sales, LLC, 24 F.4th 340 (4th Cir. 2022), affirmed the dismissal of a False Claims Act (“FCA”) qui tam lawsuit...more
On February 23, 2022, the U.S. District Court for the Eastern District of Texas gutted portions of the interim final rule affecting the independent dispute resolution (“IDR”) process of the No Surprises Act (the “Act”). Tex....more
A few weeks ago, the U.S. Court of Appeals for the Fourth Circuit answered a critical inquiry in the False Claims Act (“FCA”) context: does a defendant violate the FCA when it’s reading of the regulation is objectionably...more
3/10/2022
/ Appellate Courts ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Justice (DOJ) ,
Dissenting Opinions ,
Fair Credit Reporting Act (FCRA) ,
False Claims Act (FCA) ,
Manufacturers ,
Medicaid ,
Medicaid Drug Rebate Program ,
Omnicare ,
Qui Tam ,
Safeco